Systemic Sclerosis (SSc) Overview

Save information for later
Sign Up

Learn About Systemic Sclerosis (SSc)

What is the definition of Systemic Sclerosis (SSc)?
Systemic sclerosis, also called scleroderma, is an autoimmune disorder that cause the skin to tighten and harden. Systemic sclerosis can also affect the blood vessels, digestive tract, and internal organs.
What are the symptoms of Systemic Sclerosis (SSc)?
Systemic sclerosis can be localized, limited, or spread more widely (diffuse). Symptoms of systemic sclerosis include hardening and tightening of the skin; skin thickening; skin swelling; itchiness; skin discoloration; red spots; calcium deposits under the skin; pale, blue, red, painful, or numb fingers and toes (Raynaud’s syndrome); heartburn; difficulty swallowing; bloating; diarrhea; constipation; fecal incontinence; dizziness; shortness of breath; high blood pressure; pulmonary hypertension; swelling in the legs and feet; irregular heartbeat; and heart failure.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Systemic Sclerosis (SSc)?
There is currently no cure for systemic sclerosis. Treatment for systemic sclerosis includes medications such as vasodilators, immunosuppressants, antacids, antibiotics, and pain relievers; physical or occupational therapies; stem cell transplants; and organ transplantation.
Who are the top Systemic Sclerosis (SSc) Local Doctors?
Dr. Gerald Y. Ho
Rheumatology
Dr. Gerald Y. Ho
Rheumatology

Arthritis And Osteoporosis Medical Center, Inc

5451 La Palma Ave, Suite 25, 
La Palma, CA 
 (2.7 mi)
714-670-1340
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gerald Ho is a Rheumatologist in La Palma, California. Dr. Ho and is rated as an Advanced provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Rheumatoid Arthritis (RA), Osteoporosis, Postmenopausal Osteoporosis, and Scleroma.

Dr. Nicholas Y. Kim
Rheumatology
Dr. Nicholas Y. Kim
Rheumatology
5730 Beach Blvd, Suite 200, 
Buena Park, CA 
 (0.7 mi)
714-594-6962
Languages Spoken:
English

Nicholas Kim is a Rheumatologist in Buena Park, California. Dr. Kim and is rated as an Experienced provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Bursitis, Muscle Spasms, Tenosynovitis, and Rheumatoid Vasculitis.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Andrew C. Phan
Rheumatology
Dr. Andrew C. Phan
Rheumatology

Providence Medical Foundation

1950 Sunny Crest Dr, Suite 2900, 
Fullerton, CA 
 (4.2 mi)
714-992-5350
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Phan is a Rheumatologist in Fullerton, California. Dr. Phan and is rated as an Experienced provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Scleroderma, Psoriatic Arthritis, Systemic Sclerosis (SSc), and Scleroma.

View All Doctors
What are the latest Systemic Sclerosis (SSc) Clinical Trials?
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Who is this study for: Adult patients with Metastatic or Unresectable Solid Tumors
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 1

Summary: This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and sprea...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis
A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis
Enrollment Status: Recruiting
Publish Date: February 24, 2025
Intervention Type: Other, Biological
Study Phase: Phase 2

Summary: The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)

View All Clinical Trials